Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T18:57:51.541Z.
Calculation as of: 2026-10-06T18:57:51.541Z.
Quote observation: 2026-10-06T18:54:59.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 7123ab057bb1841ee835f9c71551e031ef341e3ba9317ad50f2164e9d5c136ac
PEG RATIO
N/A
Market Cap
$214.92M
PEG Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$211.56M
PEG Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PEG RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Niagen Bioscience Inc (NAGE) | $213.66M | N/A | N/A | N/A | N/A |
| Lyell Immunopharma, Inc. (LYEL)vs › | $213.95M | N/A | N/A | N/A | N/A |
| Prelude Therapeutics Incorporated (PRLD)vs › | $214.92M | N/A | N/A | N/A | N/A |
| Compugen Ltd. (CGEN)vs › | $211.80M | N/A | N/A | N/A | N/A |
| Entrada Therapeutics, Inc. (TRDA)vs › | $210.77M | N/A | N/A | N/A | N/A |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $211.56M | N/A | N/A | N/A | N/A |
| Electra Therapeutics Inc. (ETRA)vs › | $209.74M | N/A | N/A | N/A | N/A |
| Pro-Dex, Inc. (PDEX)vs › | $208.05M | 0.54 | 1.10 | 0.76 | 0.66 |
| Sionna Therapeutics, Inc. (SION)vs › | $206.79M | N/A | N/A | N/A | N/A |
| Keros Therapeutics, Inc. (KROS)vs › | $222.23M | N/A | N/A | N/A | N/A |
PEG Ratio
N/A
P/E Ratio
14.4
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
